Discovery Hub
immunoglobulin G4-kappa, anti-[Homo sapiens C1q (complement C1q)], monoclonal antibody (H-gamma4 heavy chain (1-448) [VH Musmus/Homsap (Mus musculus IGHV1-64*01 (82.5%) -(IGHD) -IGHJ4*01 (92.9%) S123>T (116)/Homo sapiens IGHV1-46*01 (79.4%) -(IGHD) -IGHJ6*01 (92.9%), CDR-IMGT [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo sapiens IGHG4*01, nG4m(a) CH2 L92, 12-G4v5 h P10, 6-G4v3 CH2 E1.2 (CH1 (122-219), hinge 1-12 S10>P (229) (220-231), CH2 L1.2>E (236), L92 (310) (232-341), CH3 (342-446), CHS (447-448)) (122-448)], (135-214')-disulfide with L-kappa light chain (1'-214') [V-KAPPA Musmus/Homsap (Mus musculus IGKV16-104*01 (89.5%) -IGKJ2*03 (90.9%) S120>Q (100')/Homo sapiens IGKV1-9*03 (80.9%) -IGKJ2*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')]; dimer (227-227'':230-230'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1SV, lacking the glutamine synthetase (GS-KO) gene, glycoform alfa)

immunoglobulin G4-kappa, anti-[Homo sapiens C1q (complement C1q)], monoclonal antibody (H-gamma4 heavy chain (1-448) [VH Musmus/Homsap (Mus musculus IGHV1-6401 (82.5%) -(IGHD) -IGHJ401 (92.9%) S123>T (116)/Homo sapiens IGHV1-4601 (79.4%) -(IGHD) -IGHJ601 (92.9%), CDR-IMGT [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo sapiens IGHG401, nG4m(a) CH2 L92, 12-G4v5 h P10, 6-G4v3 CH2 E1.2 (CH1 (122-219), hinge 1-12 S10>P (229) (220-231), CH2 L1.2>E (236), L92 (310) (232-341), CH3 (342-446), CHS (447-448)) (122-448)], (135-214')-disulfide with L-kappa light chain (1'-214') [V-KAPPA Musmus/Homsap (Mus musculus IGKV16-10401 (89.5%) -IGKJ203 (90.9%) S120>Q (100')/Homo sapiens IGKV1-903 (80.9%) -IGKJ201 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')]; dimer (227-227'':230-230'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1SV, lacking the glutamine synthetase (GS-KO) gene, glycoform alfa)

Huntington Disease

Annexon, Inc.monoclonal_antibodyPhase 2Dormant

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 81/ 100

Competitive context

25 Active assets in the Huntington Disease cohort.

Asset / Sponsor	Phase	Rating
Deutetrabenazine Teva Branded Pharmaceutical Products R&D LLC	Phase 4	BBB
Tetrabenazine William Ondo, MD	Phase 4	BBB
ro7234292 Hoffmann-La Roche	Phase 3	BBB
Dimebon Medivation, Inc.	Phase 3	BB
Pridopidine Prilenia	Phase 3	BB

View all 50 →

Same molecule, other indications

immunoglobulin G4-kappa, anti-[Homo sapiens C1q (complement C1q)], monoclonal antibody (H-gamma4 heavy chain (1-448) [VH Musmus/Homsap (Mus musculus IGHV1-64*01 (82.5%) -(IGHD) -IGHJ4*01 (92.9%) S123>T (116)/Homo sapiens IGHV1-46*01 (79.4%) -(IGHD) -IGHJ6*01 (92.9%), CDR-IMGT [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo sapiens IGHG4*01, nG4m(a) CH2 L92, 12-G4v5 h P10, 6-G4v3 CH2 E1.2 (CH1 (122-219), hinge 1-12 S10>P (229) (220-231), CH2 L1.2>E (236), L92 (310) (232-341), CH3 (342-446), CHS (447-448)) (122-448)], (135-214')-disulfide with L-kappa light chain (1'-214') [V-KAPPA Musmus/Homsap (Mus musculus IGKV16-104*01 (89.5%) -IGKJ2*03 (90.9%) S120>Q (100')/Homo sapiens IGKV1-9*03 (80.9%) -IGKJ2*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')]; dimer (227-227'':230-230'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1SV, lacking the glutamine synthetase (GS-KO) gene, glycoform alfa) is also rated in:

amyotrophic lateral sclerosisDormant

CCC

Indicative ·

54 / 100

View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →